Opinion|Videos|February 17, 2025
Sequencing Sections for Patients With Both BRCA Mutations and Early-Stage TNBC
Author(s)Rebecca A. Shatsky, MD, Casey Degen, MD
Panelists discuss factors influencing the decision to continue adjuvant immunotherapy for patients achieving pathologic complete response (pCR) with pembrolizumab-containing therapy, weighing the benefits against risks and considering the role of biomarkers. They also explore sequencing decisions for patients with both BRCA mutations and early-stage triple-negative breast cancer (TNBC), focusing on the prioritization of PARP inhibition versus immunotherapy and situations where both may be recommended. Additionally, they discuss approaches to monitoring and managing immune-related adverse events, including baseline screening and ongoing management protocols.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Dr. Shatsky asks Dr. Degen: For patients achieving pCR with pembrolizumab-containing therapy, what factors influence your decision about adjuvant immunotherapy continuation? (31: 28 -
- How do you weigh the potential benefits against risks?
- What role do biomarkers play in this decision?
- Dr. Degen asks Dr. Shatsky: How do you approach sequencing decisions for patients with both BRCA mutations and early-stage TNBC? (33:51
- What factors guide your prioritization of PARP inhibition versus immunotherapy?
- Are there specific scenarios where you recommend both approaches?
- Dr. Shatsky asks Dr. Degen: Could you discuss your approach to immune-related adverse event monitoring and management?
- What is your protocol for baseline screening and ongoing monitoring?
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Firmonertinib did not significantly improve BICR-assessed PFS vs platinum/pemetrexed chemotherapy in first-line EGFR exon 20–mutant NSCLC in FURVENT trial.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
3
Firmonertinib Fails to Meet PFS End Point in First-Line EGFR Exon 20 Insertion–Mutant NSCLC
4
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
5